Literature DB >> 8100808

Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance.

A P de Bruïne1, T Wiggers, C Beek, A Volovics, M von Meyenfeldt, J W Arends, F T Bosman.   

Abstract

The occurrence of endocrine cells in 350 cases of colorectal adenocarcinoma was studied by immunohistochemistry for chromogranin A (CGA). The hormone profile of endocrine tumor cells, the correlation between endocrine differentiation and presence of other colorectal epithelial-cell lineages and the prognostic relevance of endocrine differentiation in colorectal cancer were investigated. CGA-positive tumor cells were found in 30% of cases, 21% showing moderate positivity and 9.0% extensive positivity. Of CGA-positive tumors, 70% additionally produced neurohormones, mainly indigenous to normal colorectal epithelium: 55% showed immunoreactivity for glucagon-like substances, 20% for serotonin and 10% for somatostatin, PYY and HCG. No immunoreactivity was found for various neurohormones not normally produced by colorectal endocrine cells. CGA-positive tumors tended to be more aggressive than CGA-negative tumors. Especially, tumors with extensive CGA positivity showed shorter survival, which was most apparent within Dukes' stage C. In multivariate analysis, extensive CGA positivity was an independent indicator of poor prognosis. CGA immunoreactivity significantly correlated with mucin production, but not with expression of secretory component (SC), a columnar-cell marker. Mucin production significantly correlated with SC expression. Tumors positive for CGA but not for mucin and/or SC showed the worst prognosis. SC expression was a relatively favorable feature, and mucin-producing tumors showed intermediate behavior.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100808     DOI: 10.1002/ijc.2910540510

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  Neuroendocrine differentiation: The mysterious fellow of colorectal cancer.

Authors:  Britta Kleist; Micaela Poetsch
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

2.  Fetal and neoplastic expression of the neurotensin gene in the human colon.

Authors:  B M Evers; Z Zhou; V Dohlen; S Rajaraman; J C Thompson; C M Townsend
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

3.  Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.

Authors:  Mark Kidd; Irvin M Modlin; Shrikant M Mane; Robert L Camp; Michael D Shapiro
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

Review 4.  Classification and functions of enteroendocrine cells of the lower gastrointestinal tract.

Authors:  Ashok R Gunawardene; Bernard M Corfe; Carolyn A Staton
Journal:  Int J Exp Pathol       Date:  2011-04-25       Impact factor: 1.925

Review 5.  Restaging of colorectal cancer and PET/CT.

Authors:  Alev Çınar; Esra Arzu Gençoğlu; Meliha Korkmaz
Journal:  Ulus Cerrahi Derg       Date:  2013-06-01

6.  Inhibition by vasoactive intestinal polypeptide (VIP) of angiogenesis induced by murine Colon 26-L5 carcinoma cells metastasized in liver.

Authors:  M Ogasawara; J Murata; Y Kamitani; K Hayashi; I Saiki
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

7.  Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas.

Authors:  Marco Volante; Valerio Marci; Snezana Andrejevic-Blant; Veronica Tavaglione; Maria Carla Sculli; Marco Tampellini; Mauro Papotti
Journal:  Virchows Arch       Date:  2010-09-02       Impact factor: 4.064

Review 8.  Prognostic significance of neuroendocrine differentiation in colorectal adenocarcinoma after radical operation: a meta-analysis.

Authors:  Yu-Jie Zeng; Wei Lai; Lu Liu; Heng Wu; Xing-Xi Luo; Jie Wang; Zhong-Hua Chu
Journal:  J Gastrointest Surg       Date:  2014-02-19       Impact factor: 3.452

9.  Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.

Authors:  F Panzuto; C Severi; R Cannizzaro; M Falconi; S Angeletti; A Pasquali; V D Corleto; B Annibale; A Buonadonna; P Pederzoli; G Delle Fave
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

10.  Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.

Authors:  Patricia Grabowski; Isrid Sturm; Katharina Schelwies; Kerstin Maaser; Heinz-Johannes Buhr; Bernd Dörken; Martin Zeitz; Peter T Daniel; Hans Scherübl
Journal:  Int J Colorectal Dis       Date:  2005-06-14       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.